Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct

Cited by (348)

Items 201–300 of 348

1. Multispecific, Multivalent Antibody‐Based Molecules Engineered on the DART® and TRIDENTTM Platforms
   Ling Huang, Kalpana Shah, Bhaswati Barat, Chia‐Ying K. Lam, Sergey N. Gorlatov, Valentina C. Ciccarone, James K. Tamura, Paul A. Moore, Gundo Diedrich · 2020 · Current Protocols in Immunology
2. PSMA-targeted bispecific Fab conjugates that engage T cells
   James T. Patterson, Jason Isaacson, Lisa Kerwin, Ghazi Atassi, Rohit Duggal, Damien Bresson, Tong Zhu, Heyue Zhou, Yanwen Fu, Gunnar F. Kaufmann · 2017 · Bioorganic & Medicinal Chemistry Letters
3. Progress in adult ALL: incorporation of new agents to frontline treatment
   Jessica Taft Leonard, Wendy Stock · 2017 · Hematology
4. Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
   Xiaozhi Liao, Timothy Qi, Jiawei Zhou, Can Liu, Yanguang Cao · 2024 · Clinical Pharmacology & Therapeutics
5. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs)
   Kathrine S Rallis, Christopher Hillyar, Michail Ch. Sideris, JEFF K. DAVIES · 2021 · Anticancer Research
6. A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex
   Tao Dao, Sung Soo Mun, Tatyana Korontsvit, Abdul G. Khan, Mary Ann Pohl, Thomas White, Martin G. Klatt, David P. Andrew, Ivo C. Lorenz, David A. Scheinberg · 2022 · PLoS ONE
7. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia
   Ryan K DasGupta, Bernard Lawrence Marini, Joslyn Rudoni, Anthony J. Perissinotti · 2017 · Journal of Oncology Pharmacy Practice
8. Antibody-Based Immunotherapy for Malignant Glioma
   Patrick C. Gedeon, Katherine A. Riccione, Peter Edward Fecci, John Howard Sampson · 2014 · Seminars in Oncology
9. A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
   Brett Fleisher, Sihem Ait‐Oudhia · 2017 · OncoTargets and Therapy
10. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
    Jana Mihályová, Katarína Hradská, Tomáš Jelı́nek, Benjamin Motais, Piotr Celichowski, Roman Hájek · 2021 · International Journal of Molecular Sciences
11. Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia
    Ibrahim Taha Aldoss, Bijal Dinesh Shah, Jae H. Park, Lori S. Muffly, Aaron C. Logan, Patrick Andrew Brown, Wendy Stock, Elias Joseph Jabbour · 2023 · American Journal of Hematology
12. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia
    Naresh Bumma, Nikolaos Papadantonakis, Anjali S. Advani · 2015 · Future Oncology
13. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy
    Jae‐Ho Yoon, Seok Lee · 2024 · The Korean Journal of Internal Medicine
14. Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation
    Ayman Sayyed, Carol C. L. Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Law, Jeffrey Howard Lipton, Fotios V. Michelis, Igor Novitzky‐Basso et al. · 2024 · Transplantation and Cellular Therapy
15. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
    Matthew Joseph Wieduwilt · 2017 · Best Practice & Research Clinical Haematology
16. Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
    Manon Queudeville, Rupert Handgretinger, Martin Ebinger · 2017 · OncoTargets and Therapy
17. A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis
    Arthur J. Van De Vyver, Miro Julian Eigenmann, Meric Ovacik, Christian Pohl, Sylvia Herter, Tina Weinzierl, Tanja Fauti, Christian Klein, Thorsten Lehr, Marina Bacac et al. · 2021 · The AAPS Journal
18. A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies
    Haley M. Newman, David T. Teachey · 2022 · International Journal of Molecular Sciences
19. Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing
    Steffen Dickopf, Matthias E. Lauer, Philippe Ringler, Christian Spick, Peter Kern, Ulrich Brinkmann · 2018 · Biological Chemistry
20. Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen
    Gargi Das, J. Ptáček, Barbora Havlínová, Jana Nedvědová, Cyril Bařinka, Zora Nováková · 2023 · ACS Pharmacology & Translational Science
21. A single‐chain variable fragment‐based bispecific T‐cell activating antibody against CD117 enables T‐cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells
    Laura G. Volta, Renier Myburgh, Mara Hofstetter, Christian Koch, Jonathan D. Kiefer, Celeste Gobbi, Francesco Manfredi, Kathrin Zimmermann, Philipp Antonio Kaufmann, Serena Fazio et al. · 2024 · HemaSphere
22. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia
    Mattia Algeri, Francesca Del Bufalo, Federica Galaverna, Franco Locatelli · 2018 · Expert Review of Hematology
23. Bispecific antibodies in acute lymphoblastic leukemia therapy
    Guranda Chitadze, Anna Laqua, Marcus Lettau, Claudia Dorothea Baldus, Monika Brüggemann · 2020 · Expert Review of Hematology
24. Update on developmental therapeutics for acute lymphoblastic leukemia
    Malcolm Anders Smith · 2009 · Current Hematologic Malignancy Reports
25. Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors
    Nazanin Tatari, Xiaoyu Zhang, Shawn C. Chafe, Dillon McKenna, Keith A. Lawson, Minomi Subapanditha, Muhammad Vaseem Shaikh, Mathieu Seyfrid, Neil J. Savage, Chitra Venugopal et al. · 2022 · Frontiers in Immunology
26. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis
    Jae‐Ho Yoon, Daehun Kwag, Jong-Hyuk Lee, Gi June Min, Sung‐Soo Park, Silvia Park, Sung‐Eun Lee, Byung‐Sik Cho, Ki‐Seong Eom, Yoo‐Jin Kim et al. · 2023 · Therapeutic Advances in Hematology
27. Alternative Protein Scaffolds as Novel Biotherapeutics
    Michaela Gebauer, Arne Skerra · 2015 · AAPS advances in the pharmaceutical sciences series
28. Immunotherapy approaches to treat adult acute lymphoblastic leukemia
    Elena Maino, Massimiliano Bonifacio, Anna Maria Scattolin, Renato Bassan · 2016 · Expert Review of Hematology
29. Treatment approaches of hard-to-treat non-Hodgkin lymphomas
    Lakshminarayanan Nandagopal, Amitkumar Mehta · 2017 · Expert Review of Hematology
30. Advances in Supportive Care for Acute Lymphoblastic Leukemia
    Joselle Cook, Mark Robert Litzow · 2020 · Current Hematologic Malignancy Reports
31. Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
    Diego Conde-Royo, Luis Miguel Juarez Salcedo, Samir M. Dalia · 2020 · Drugs in Context
32. Bispecific Antibodies
    Dafne Müller, Roland E. Kontermann · 2007 · Wiley eBooks
33. Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
    Xiaoli Wen, Gaosi Xu · 2024 · OncoTargets and Therapy
34. Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia
    Priscilla Do, Lacey A Perdue, Andrew Chyong, Rae Hunter, Jodi Dougan, Curtis James Henry, Christopher C. Porter, Erik C. Dreaden · 2020 · ACS Combinatorial Science
35. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement
    Meixiao Long, Alice S. Mims, Zihai Li · 2022 · Immunological Investigations
36. A Multidisciplinary Approach to Standardizing Processes for Blinatumomab Administration
    Samantha Depadova, Christina Howlett, Kimberly Rivera · 2016 · Clinical journal of oncology nursing
37. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia
    Gautam Kishore Valecha, Uroosa Ibrahim, Sassine Ghanem, Divya Asti, Jean Paul Atallah, Terenig O. Terjanian · 2017 · Expert Review of Hematology
38. T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell
    Claudia C. Roskopf, Christian Schiller, Todd A. Braciak, Sebastian Kobold, Ingo A. Schubert, Georg H. Fey, Karl‐Peter Hopfner, Fuat S. Oduncu · 2014 · Oncotarget
39. Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review
    Harrison D. Collier‐Bain, Frankie F. Brown, Adam J. Causer, Annabelle Emery, Rebecca Oliver, Sally E. Moore, James Murray, James E. Turner, John P. Campbell · 2023 · Frontiers in Oncology
40. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
    Armin Ghobadi, Nicole C. Foley, Jared A. Cohen, Michael P. Rettig, Amanda F. Cashen, Leah Gehrs, Stephanie Christ, Emily Street, Nicholas Wallace, Julie Ritchey et al. · 2023 · Blood Advances
41. Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia
    Jessica Turner, Susan M. Schneider · 2016 · Clinical journal of oncology nursing
42. The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy
    Yun‐Hsiang Chen, Yun Wang, Cheng-Hao Liao, Shu‐Ching Hsu · 2021 · Scientific Reports
43. Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle
    Katrin Spiesberger, Florian Paulfranz, Anton Egger, Judith Reiser, Claus Vogl, Judith Rudolf-Scholik, Corina Mayrhofer, Ludger Große‐Hovest, Gottfried Brem · 2015 · PLoS ONE
44. Bispecific Antibodies
    Dafne Müller, Roland E. Kontermann · 2014 · Wiley eBooks
45. IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents
    Andreas V. Madsen, Peter Kjær Kristensen, Steffen Goletz · 2024 · Expert Opinion on Biological Therapy
46. Bispecific antibody for lung cancer: mechanisms and clinical insights
    Wei Chen, Afang Zhou, Yunfeng Zhou · 2025 · Frontiers in Immunology
47. Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy
    Mattia Schipani, Matteo Bellia, Carola Sella, Riccardo Dondolin, Mariangela Greco, Abdurraouf Mokhtar Mahmoud, Clara Deambrogi, Riccardo Moia, Gianluca Gaïdano, Riccardo Bruna · 2025 · Cancers
48. Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies
    Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito et al. · 2025 · European Journal Of Haematology
49. Compact Seahorse‐Shaped T Cell–Activating Antibody for Cancer Therapy
    Hiroto Fujii, Yoshikazu Tanaka, Hikaru Nakazawa, Aruto Sugiyama, Noriyoshi Manabe, Akira Shinoda, Nobutaka Shimizu, Takamitsu Hattori, Katsuhiro Hosokawa, Takuma Sujino et al. · 2018 · Advanced Therapeutics
50. Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach
    Asami Ueda, Mitsuo Umetsu, Takeshi Nakanishi, Kentaro Hashikami, Hikaru Nakazawa, Shuhei Hattori, Ryutaro Asano, Izumi Kumagai · 2020 · International Journal of Molecular Sciences
51. Bispecific Antibodies: Developments and Current Perspectives
    Roland E. Kontermann · 2011 · Springer eBooks
52. Novel monoclonal antibody-based therapies for leukemia
    Osmond J. D’Cruz, Fatih Mehmet Uckun · 2013
53. Tumor microenvironment as a novel therapeutic target for lymphoid leukemias
    Shahrzad Mousavi, Soheil Nouri, Arezoo Sadeghipour, Amir Atashi · 2025 · Annals of Hematology
54. Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies
    Puja Bhattacharyya, Richard Ian Christopherson, Kristen K. Skarratt, Zheng Chen, Thomas Balle, Stephen J. Fuller · 2023 · Cancers
55. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia
    Yukio Kobayashi, Iekuni Oh, Toshihiro Miyamoto, Won‐Sik Lee, Hiroatsu Iida, Hironobu Minami, Yoshinobu Maeda, Jun Ho Jang, Sung‐Soo Yoon, Su‐Peng Yeh et al. · 2021 · Asia-Pacific Journal of Clinical Oncology
56. Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
    Yutaka Shimazu, Toshio Kitawaki, Tadakazu Kondo, Akifumi Takaori‐Kondo · 2023 · Cancer Immunology Immunotherapy
57. Application of a new wall-less plate technology to complex multistep cell-based investigations using suspension cells
    Gabriel Quiñones, Travis I. Moore, Katrina Nicholes, Hyunjae Lee, Sudong Kim, Laura Sun, Noo Li Jeon, Jean-Philippe Stéphan · 2012 · Blood
58. Advantages of Drug Selective Distribution in Cancer Treatment: Brentuximab Vedotin
    Luís Villela, Ana Karen Velez-Ayal, Rosa C. López-Sánchez, Jorge Martínez, José A Hernández-Hernández · 2017 · International Journal of Pharmacology
59. Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
    Josep‐María Ribera, Eulàlia Genescà, Jordi Ribera · 2020 · Therapeutic Advances in Hematology
60. Bispecific Antibodies
    Gordana Wozniak‐Knopp · 2020 · Learning materials in biosciences
61. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Hagop M. Kantarjian, Gerhard Zugmaier, Monika Brüggemann, Brent Lee Wood, Heinz A. Horst, Yi Zeng, Giovanni Martinelli · 2021 · Cancers
62. Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs
    Feinan Lu, Tao Wang, Ying Lü, Jie Chen · 2024 · The New England Journal of Statistics in Data Science
63. Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults
    Kaori Kondo, Yuho Najima, Daichi Sadato, Chizuko Hirama, Kana Kato, Yasutaka Sadaga, Chika Kato, Satoshi Sakai, Yasuhiro Kambara, Yoshimi Nabe et al. · 2025 · Leukemia Research
64. Bispecific T-cell engagers (BiTE): a review of tarlatamab in small cell lung cancer
    Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Tolu Comfort Oladipo, Adedamola Solomon Oyenuga, Victor Olamiposi Olaiya, Chidera Stanley Anthony, MD, Chinonyelum Emmanuel Agbo, Weam Salih Abdallah, Adewunmi Akingbola, Olanipekun Lanny Ntukidem · 2025 · Clinical & Translational Oncology
65. Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies
    Stacy Cooper, Patrick Andrew Brown · 2019 · Resistance to targeted anti-cancer therapeutics
66. Development and prospects for bispecific antibody-based therapeutics in cancer and other applications
    Lawrence G. Lum, Zaid S Al-Kadhimi · 2008 · Expert Opinion on Drug Discovery
67. Blinatumomab in acute lymphoblastic leukemia
    Xavier Thomas, Caroline Lejeune · 2016 · Expert Review of Anticancer Therapy
68. Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers
    Mengyao Xu, Syem Barakzai, Raj Kumar, Irva E. Veillard, Eugene Kim, Amy J. Bregar, Eric Lawernce Eisenhauer, Richard T. Penson, Sara Bouberhan, Jennifer Filipi et al. · 2025 · Signal Transduction and Targeted Therapy
69. Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer
    Kodchakorn Mahasongkram, Kittirat Glab-ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, Wanpen Chaicumpa · 2023 · Vaccines
70. Oncolytic viruses expressing MATEs facilitate target-independent T-cell activation in tumors
    Malin Peter, Bettina Mundt, Arne Menze, Norman Woller, Valery Volk, Amanda M. Ernst, Leon A Öhler, Steven Roger Talbot, Heiner H. Wedemeyer, Christine Susanne Falk et al. · 2025 · EMBO Molecular Medicine
71. Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task
    Carl H. June · 2015 · Cancer Immunology Research
72. Anti-CD19 monoclonal antibodies in acute lymphoblastic leukemia in children
    Alexander I. Karachunskiy, Yu. V. Rumyantseva, Av Stackelberg · 2016 · Russian Journal of Pediatric Hematology and Oncology
73. Multiple Myeloma: Therapeutic Delivery of Antibodies and Aptamers
    Neret Pujol-Navarro, Mohammed M. Al Qaraghuli, Karina Kubiak-Ossowska, Manal Alsaadi, Gillian Abigail Horne, Richard L Soutar, Elpiniki Paspali, Valerie Anne Ferro, Mark Thomas Shaw Williams, Paul Alexander Mulheran · 2021 · Therapeutic Delivery
74. Current Immunotherapeutic Treatments in Colon Cancer
    Zodwa Dlamini, Thandeka Khoza, Rodney Hull, Mpho Susan Choene, Zilungile L. Mkhize‐Kwitshana · 2016 · InTech eBooks
75. Bispecific T Cell Engager for Cancer Therapy
    Patrick A. Baeuerle, Gerhard Zugmaier, Dominik Rüttinger · 2011 · Springer eBooks
76. Blinatumomab added to conditioning regimen of allogeneic hematopoietic stem cell transplantation for adult MRD - positive acute lymphoblastic leukemia: a single-center case series
    Hui Fu, Yanmin Zhao, Huarui Fu, Meng Liu, Congxiao Zhang, Yang Li, He Huang, Jimin Shi, Jian Yu · 2025 · Hematology
77. T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases
    A. S. Vdovin, Н. А. Быкова, Grigory Aleksandrovich Efimov · 2017 · Molecular Biology
78. Woodchuck Hepatitis Virus Post-Transcriptional Regulation Element (WPRE) Promotes Anti-CD19 BiTE Expression in Expi293 Cells
    Reza Moazzami, Hasan Mirzahoseini, Leila Nematollahi, Farzaneh Barkhordari, Mozhgan Raigani, Fatemeh Hajari Taheri, Fereidoun Mahbudi, Fatemeh Davami · 2021 · Iranian Biomedical Journal
79. A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
    Yasuto Yamamoto, Takeo Shimasaki, Yasuhito Ishigaki, Shino Fujimoto, Yoshimitsu Takahashi, Shiori Kimura, Keiko Aijo, Mami Takayanagi, Shuichi Mizuta, Togen Masauji et al. · 2022 · Medicina
80. SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia
    Ashley E. Pinchinat, Sumit Gupta, Stacy Cooper, Rachel E. Rau · 2022 · Clinical Lymphoma Myeloma & Leukemia
81. Recombinant Bispecific Antibodies for Cancer Therapy
    Dafne Müller, Roland E. Kontermann · 2011 · Cell engineering
82. High-throughput cytotoxicity and antigen-binding assay for screening small bispecific antibodies without purification
    Aruto Sugiyama, Mitsuo Umetsu, Hikaru Nakazawa, Teppei Niide, Ryutaro Asano, Takamitsu Hattori, Izumi Kumagai · 2018 · Journal of Bioscience and Bioengineering
83. Blinatumomab-Associated Neurological Adverse Events
    Gulrayz Ahmed, Rafiullah Khan, Chandana Kamireddy, Huda Qadir, Imran Ameen Khan, Zartash Gul · 2019 · American Journal of Therapeutics
84. [Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia].
    Xiao-Lan Li, Lipeng Liu, Fang Liu, Ye Guo, Xiaojuan Chen, Xiaofan Zhu, Wenyu Yang · 2023 · PubMed Central
85. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
    Mark E. Gurney, Mark Robert Litzow · 2023 · Elsevier eBooks
86. Clinical Experience with Bispecific T Cell Engagers
    Nicola Gökbuget · 2019 · Recent results in cancer research/Recent Results in Cancer Research
87. Development of T‐Cell‐Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B‐Cell Malignancies
    Patrick A. Baeuerle · 2018 · Wiley eBooks
88. Probing the Dynamic Strength of Biomolecular Interactions with Single-Cell Centrifugation
    Hans Bergal, Koji Kinoshita, Wesley P. Wong · 2025 · ACS Central Science
89. SOHO State of the Art Updates and Next Questions | Incorporating Immunotherapy into Upfront Acute Lymphoblastic Leukemia Therapy
    Ajoy Dias, Mark Robert Litzow · 2025 · Clinical Lymphoma Myeloma & Leukemia
90. Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis
    Yu Sun, Shi Yu Guo, Si Qi Wang, Rui Tong Li, Xi Ran Qiu, Xing Chen Dong, Shuang Liu, Hui Shen, Mao‐Mao An · 2025 · PLoS Pathogens
91. Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection
    Guanda Jiao, Hongsen Peng, Yiqi Yang, Yang Liu, Xiaoxi Liu, Yuanjia Hu, Yeneng Dai, Z Li, Qi Zhao · 2026 · Molecular Cancer
92. T cell engagers in autoimmune diseases
    Ricardo Grieshaber‐Bouyer, Lei Wu, Georg Andreas Schett, Patrick A. Baeuerle · 2026 · Nature reviews. Immunology
93. Effective Cancer Immunotherapy – Are We There Yet?
    J. Lynne Williams, Evon Kashat · 2015 · American Society for Clinical Laboratory Science
94. The Epigenetic Regulation of Blinatumomab Gene Expression: Tumor Cell-dependent T cell Response against Lymphoma Cells and Cytotoxic Activity.
    Fatemeh Naddafi, Fereidoun Mahboudi, Maryam Tabarzad, Zahra Aliabadi Farahani, Farshad H. Shirazi, Fatemeh Davami · 2019 · PubMed Central
95. Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis
    Ben Ponvilawan, Pongthep Vittayawacharin, Pattaraporn Tunsing, Weerapat Owattanapanich · 2021 · Technology in Cancer Research & Treatment
96. Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases
    Wei-Han Huang, Chunrong Tong, Tong Wu, Yun‐Chu Lin, Chi‐Cheng Li · 2020 · BLOOD CELL THERAPY / The official journal of APBMT
97. In Vitro Assays for Assessing Potential Adverse Effects of Cancer Immunotherapeutics
    Jinze Li, Mayur S. Mitra, Gautham K. Rao · 2020 · Methods in pharmacology and toxicology
98. Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential
    Chanchal Kumar, Rajat Pratap Singh, Mrigendra Kumar Dwivedi, Ajay Amit · 2021 · Springer eBooks
99. [Chinese consensus for the bispeific T cell engager in the treatment of B-cell acute lymphoblastic leukemia (2022)].
    2022 · PubMed Central
100. Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
     Agnes Banaszek · 2013 · Online Publication Service of Würzburg University (Würzburg University)